First-in-human phase i study of single-agent vanucizumab, a first-in-class bispecific anti-angiopoietin-2/anti-VEGF-A antibody, in adult patients with advanced solid tumors - Hidalgo, M; Martinez-Garcia, M; Le Tourneau, C (Clin Cancer Res, 2018)